Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC
Anti-amyloid antibodies for the treatment of Alzheimer´s disease (AD) are currently being evaluated for approval and reimbursement in Europe. An approval brings opportunities, but also challenges to health care systems across Europe. The objective of this position paper is to provide guidance from e...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
24 May 2025
|
| In: |
Alzheimer's research & therapy
Year: 2025, Jahrgang: 17, Pages: 1-9 |
| ISSN: | 1758-9193 |
| DOI: | 10.1186/s13195-025-01766-y |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13195-025-01766-y Verlag, kostenfrei, Volltext: https://alzres.biomedcentral.com/articles/10.1186/s13195-025-01766-y |
| Verfasserangaben: | Kristian S. Frederiksen, Mercé Boada, Bruno Dubois, Sebastiaan Engelborghs, Giovanni B. Frisoni, Jean Georges, Jakub Hort, Linus Jönsson, Milica G. Kramberger, Pierre-Jean Ousset, Nikolaos Scarmeas, Reinhold Schmidt, Jonathan M. Schott, Luiza Spiro, Gunhild Waldemar, Bengt Winblad, Frank Jessen and Lutz Frölich |
| Zusammenfassung: | Anti-amyloid antibodies for the treatment of Alzheimer´s disease (AD) are currently being evaluated for approval and reimbursement in Europe. An approval brings opportunities, but also challenges to health care systems across Europe. The objective of this position paper is to provide guidance from experts in the field in terms of navigating implementation. |
|---|---|
| Beschreibung: | Gesehen am 01.09.2025 |
| Beschreibung: | Online Resource |
| ISSN: | 1758-9193 |
| DOI: | 10.1186/s13195-025-01766-y |